Comparison of oral betahistine with intravenous diazpam in acute peripheral vertigo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112208104N2

Enrollment

100

Registered

2012-09-16

Start date

2011-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute peripheral vertigo. Diseases of the ear and mastoid process

Interventions

Intervention 1: beta histine 8 mg as treatment and stilled water 5 ml as placebo was given to first group. Intervention 2: Diazepam 5 mg intravenous and oral placebo was given to second group.

Treatment - Drugs

beta histine 8 mg as treatment and stilled water 5 ml as placebo was given to first group

Diazepam 5 mg intravenous and oral placebo was given to second group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patiets over 18 yeras old with peripheral acute vertigo Exclusion criteria: contraindications of diazepam and betahistine; advanced cardiac, pulmonary and cerebrovascular diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Symptom control. Timepoint: 0,2,4 and 6 hours after treatment. Method of measurement: Vertigo severity chart.	—

Secondary

Measure	Time frame
Occurance of drug side effects. Timepoint: during the first 6 hours. Method of measurement: Monitoring the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Amin Zare

Tehran University of Medical Sciences

mazare74@yahoo.com+98 21 6652 5327

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026